NCT00325546View on ClinicalTrials.gov

Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

PHASE3CompletedINTERVENTIONAL

Enrollment

643

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Obesity

Interventions

DRUG

Rimonabant (SR141716)

DRUG

Placebo

Trial Locations (3)

105

Sanofi-Aventis, Taipei

200040

Sanofi-Aventis, Shanghai

135-755

Sanofi-Aventis, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY